Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis

Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis
复制标题

DOI:
10.1002/jcp.24145
复制
发表时间:
2013-02-01
影响因子:
5.6
通讯作者:
Paradiso, Angelo
Paradiso, Angelo
中科院分区:
生物学2区
文献类型:
--
作者:
Bellizzi, Antonia;Sebastian, Sinto;Paradiso, Angelo

文献摘要

被引文献

相似文献

尽管在非晚期癌症中取得了相对较好的治疗结果,但晚期结肠癌的预后仍然较差,这取决于疾病的局部或远处复发。导致复发的因素之一被认为是癌症干细胞(CSC)或肿瘤起始细胞,它们是一群能够通过自我更新自我延续并产生分化细胞的癌细胞群体,被认为是导致肿瘤复发的原因。这项研究全面探讨了组织源性干细胞在结肠癌发生及其肝脏转移过程中可能发挥的作用。直接从手术室获取结肠癌、非肿瘤组织和肝转移的新鲜手术标本,进行检查并立即进行处理。 CSCs 在无血清条件下选择,并通过 CD44 和 CD133 表达水平进行表征。然后在石蜡包埋的组织和从同一组结肠癌患者的外周血中分离的循环肿瘤细胞中研究CD133(+)/CD44(+)细胞群。我们的数据表明,与原始肿瘤不同,来自血液和肝转移的细胞群的转移特性似乎与CD133阳性和CD44阳性表型严格相关。 J.细胞。生理学。 228:408415,2013。(C)2012 Wiley 期刊公司。
Although relatively good therapeutic results are achieved in non-advanced cancer, the prognosis of the advanced colon cancer still remains poor, dependent on local or distant recurrence of the disease. One of the factors responsible for recurrence is supposed to be cancer stem cells (CSCs) or tumor-initiating cells, which are a population of cancer cells with ability to perpetuate themselves through self-renewal and to generate differentiated cells, thought to be responsible for tumor recurrence. This study globally approach the possible role of tissue-derived stem cells in the initiation of colon cancer and its metastatic process in the liver. Fresh surgical specimens from colon cancer, non-tumor tissue and liver metastasis were obtained directly from the operating room, examined, and immediately processed. CSCs were selected under serum-free conditions and characterized by CD44 and CD133 expression levels. CD133(+)/CD44(+) cell populations were then investigated in paraffin-embedded tissues and circulating tumor cells isolated from peripheral blood of the same group of colon cancer patients. Our data demonstrate that metastatic properties of cell populations from blood and liver metastasis, differently from primitive tumors, seem to be strictly related to the phenotype CD133 positive and CD44 positive. J. Cell. Physiol. 228: 408415, 2013. (C) 2012 Wiley Periodicals, Inc.